Exhibit 99.1
PRESS RELEASE
Investor Contact:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
LATHAM, N.Y.--(BUSINESS WIRE)--Jul. 16, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s
vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2024, which ended May 31, 2024.
Fiscal Year 2024 Fourth Quarter Highlights
|
Quarter Ended
|
||
|
May 31, 2024
|
Pro Forma* YoY Growth
|
|
|
Pro Forma* Net Sales
|
$71.1 million
|
1.9%
|
|
Med Tech Net Sales
|
$29.3 million
|
11.3%
|
|
Med Device Net Sales
|
$41.8 million
|
(3.8)%
|
| • |
GAAP Gross margin of 54.3%
|
| • |
GAAP loss per share of $(0.33)
|
| • |
Adjusted loss per share of $(0.05)
|
| • |
FDA 510(k) clearance and CE Mark approval for AlphaVac F18 System for the treatment of Pulmonary Embolism (PE)
|
| • |
Subsequent to the end of the fiscal quarter, announced share repurchase program for up to $15.0 million of its outstanding common shares
|
Fiscal Year 2024 Highlights
|
Year Ended
|
||
|
May 31, 2024
|
Pro Forma* YoY Growth
|
|
|
Pro Forma* Net Sales
|
$270.7 million
|
5.3%
|
|
Med Tech Net Sales
|
$106.0 million
|
10.1%
|
|
Med Device Net Sales
|
$164.8 million
|
2.4%
|
1
| • |
GAAP Gross margin of 50.9%
|
| • |
Pro Forma gross margin of 53.8%
|
| • |
GAAP** loss per share of $(4.59)
|
| • |
Adjusted loss per share of $(0.45)
|
| • |
Reached settlement agreement with Becton, Dickinson and C.R. Bard, ending decade-long intellectual property litigation
|
| • |
Initiated transition of manufacturing operations to a fully outsourced model to drive efficiencies and cost savings
|
| • |
Optimized Med Device business, including the divestiture of its Dialysis and BioSentry businesses, as well as the PICC and Midline product portfolios, and discontinued the sale of its RadioFrequency products and Syntrax support
catheter products
|
| • |
In conjunction with divestitures, repaid all amounts outstanding under its $50 million Credit Agreement
|
*”Pro forma” results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC and Midline product portfolios divested in February 2024, as well as the
discontinued Radiofrequency and Syntrax products. “As Reported” results include sales of the respective products prior to their divestiture or discontinuance.
**GAAP Loss per share includes a $159.5 million goodwill impairment and $19.3 million related to the previously announced settlement of IP litigation.
“We capped off a transformative 2024 with a solid fourth quarter, largely driven by a second straight quarter of double-digit increases in our Med Tech
business as Auryon and NanoKnife, delivered strong revenue growth,” commented Jim Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. “Within our Mechanical Thrombectomy segment, we achieved key milestones by receiving
both FDA 510(k) clearance and CE Marking for AlphaVac in the treatment of pulmonary embolism. These indications open up multiple large, fast-growing markets, and helped to drive a more than 68% sequential increase in AlphaVac revenue during
the fourth quarter.”
Mr. Clemmer continued, “Over the last three years, AngioDynamics has undergone a significant transformation to position ourselves for long-term success. We now have an
optimized, stable, cash-generating Med Device business, which, in combination with the strength of our balance sheet, allows us to aggressively pursue large, fast-growing global market opportunities with our highly innovative Med Tech
portfolio to drive accelerated, profitable growth moving forward.”
“We view 2025 as an inflection point in the trajectory of our business. We expect to continue to deliver strong revenue growth within our Med Tech business as we execute
on key commercial initiatives, including multiple significant international expansion opportunities and the broader launch of AlphaVac for PE. The increased scale of our Med Tech business, in combination with the optimization of our Med Device
business, will allow us to begin to see increasing leverage as we exit the year. Operationally, we will continue to work through the transition of our manufacturing model to reduce overhead costs and improve margins in 2026 and beyond.”
2
Fourth Quarter 2024 Financial Results
Unless otherwise noted, all financial results below are presented on a pro forma basis excluding the Dialysis and BioSentry businesses divested in June 2023, the PICC,
Midline, and tip location product portfolios divested in February 2024, and the RadioFrequency and Syntrax support catheter products discontinued in February 2024.
Net sales for the fourth quarter of fiscal year 2024 were $71.1 million, an increase of 1.9% compared to the prior-year quarter. Foreign currency translation did not
have a significant impact on the Company's net sales in the quarter.
Med Tech net sales were $29.3 million, an 11.3% increase from $26.4 million in the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, the
thrombus management platform and the NanoKnife irreversible electroporation platform. Growth was driven by Auryon sales during the quarter of $13.0 million, which increased 12.0%, NanoKnife disposable sales of $5.4 million, representing an
increase of 18.0% compared to the fourth quarter of fiscal 2023, and AlphaVac sales of $1.9 million, an increase of 6.8% over the prior year.
Med Device net sales were $41.8 million, a decrease of 3.8% compared to $43.4 million in the prior-year period.
U.S. net sales in the fourth quarter of fiscal 2024 were $60.8 million, an increase of 4.3% from $58.3 million a year ago. International net sales were $10.3 million, a
decrease of 9.9%, compared to $11.5 million a year ago.
Gross margin for the fourth quarter of fiscal 2024 was 54.3%, which was flat compared to the fourth quarter of fiscal 2023, but up 320 basis points sequentially from
51.1% in the third quarter. Gross margin for the Med Tech business was 64.1%, a decrease of 70 basis points from the fourth quarter of fiscal 2023 due to product mix and increased hardware depreciation. Gross margin for the Med Device
business was 47.4%, a decrease of 60 basis points compared to the fourth quarter of fiscal 2023 primarily due to retained manufacturing overhead costs associated with the discontinuation of certain Medical Device products.
The Company recorded a GAAP net loss of $13.4 million, or a loss per share of $0.33, in the fourth quarter of fiscal 2024. Excluding the items show in the non-GAAP
reconciliation table below, adjusted net loss for the fourth quarter of fiscal 2024 was $2.2 million, or a loss per share of $0.05. This compares to an adjusted net loss during the fiscal fourth quarter of 2023 of $4.3 million, or a loss per
share of $0.11.
Adjusted EBITDA in the fourth quarter of fiscal 2024, excluding the items shown in the reconciliation table below, was $1.5 million, compared to $1.3 million in the
fourth quarter of fiscal 2023.
In the fourth quarter of fiscal 2024, the Company generated $5.0 million in operating cash, which was inclusive of a $3 million payment to Bard associated with the
Company’s patent litigation settlement.
3
Full-Year 2024 Financial Results
Unless otherwise noted, all financial results below are presented on a pro forma basis excluding the Dialysis and BioSentry businesses divested in June 2023, the PICC
and Midline product portfolios divested in February 2024, and the RadioFrequency and Syntrax support catheter products discontinued in February 2024.
Net sales were $270.7 million, an increase of 5.3%, compared to $257.2 million for the prior year period.
Med Tech net sales were $106.0 million, a 10.1% increase from the prior year period. Med Device net sales were $164.8 million, an increase of 2.4% from the prior year
period.
Gross margin declined by 110 basis points to 53.8% from 54.9% a year ago due to product and geographic mix, as well as retained manufacturing overhead costs associated
with the discontinuation of certain Medical Device products.
The Company's GAAP net loss was $184.3 million, or a loss per share of $4.59, compared to a net loss of $52.4 million, or a loss per share of $1.33, a year ago. This
includes a goodwill impairment charge of $159.5 million, settlement charge of $19.3 million and asset impairment charges totaling $6.8 million related to the transition to outsourced manufacturing and discontinuation of Syntrax.
Excluding the items shown in the non-GAAP reconciliation table below, adjusted net loss was $18.2 million, with adjusted loss per share of $0.45, compared to adjusted
net loss of $21.8 million, or adjusted loss per share of $0.55, a year ago.
Adjusted EBITDA, excluding the items shown in the reconciliation table below, was a loss of $3.2 million, compared to a loss of $3.0 million for the prior year.
At May 31, 2024, the Company had $76.1 million in cash and cash equivalents compared to $44.6 million, which included $50 million of debt, at May 31, 2023. During the
first fiscal quarter of 2024, the Company repaid all amounts outstanding under its then existing credit agreement, and currently has no long-term debt.
Pro Forma 2024 Performance
In addition to actual results, the tables accompanying this press release reflect pro forma results, which exclude the Dialysis and BioSentry businesses divested in
June 2023, the PICC, Midline, and tip location product portfolios divested in February 2024, and the RadioFrequency and Syntrax support catheter products discontinued in February 2024.
4
Fiscal Year 2025 Financial Guidance
For fiscal year 2025, the Company expects:
| • |
Net sales to be in the range of $282 to $288 million, representing growth of between 4.2% – 6.4% over fiscal 2024 pro forma revenue of $270.7 million
|
| • |
Med Tech net sales are expected to grow in the range of 10% to 12%
|
| • |
Med Device net sales are expected to grow in the range of 1% to 3%
|
| • |
Gross margin to be approximately 52% to 53%
|
| • |
Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal 2024
|
| • |
Adjusted loss per share in the range of $0.38 to $0.42, compared to pro forma adjusted loss per share of $0.45 in fiscal 2024
|
Share Repurchase Program
Today, the Company announced that the Board of Directors has approved a stock repurchase program authorizing the Company’s management team to purchase up to $15.0
million of its outstanding common shares.
The timing and amount of any share repurchases under the authorization will be determined by management at its discretion and based on market conditions and other
considerations.
Q4 and Full Year 2024 Key Takeaways
AlphaVac F18 System Pulmonary Embolism (PE) Indication Expansions
In April of fiscal 2024, the Company announced that the Food and Drug Administration has cleared the AlphaVac F18 System for the treatment of pulmonary embolism (PE), a
condition affecting around 900,0001,2 people in the United States annually and the third leading cause of cardiovascular mortality in the nation. The expanded
FDA indication allows for the utilization of the AlphaVac F18 System in the non-surgical removal of thrombi or emboli from the venous vasculature, reducing thrombus burden and improving right ventricular function in patients with PE.
In May of fiscal 2024, the Company received CE Mark approval of the AlphaVac F18 System for PE. The CE Mark allows AngioDynamics to provide innovative solutions to more
healthcare professionals treating patients diagnosed with PE in the European Union (EU), where an estimated 435,0003 PE events occur each year in the six largest
EU countries. Compared to the United States, the prevalence of PE is higher for patients admitted to the emergency department in Europe, and European patients also had higher acuity and worse outcomes4.
For risk information, visit https://bit.ly/Angio-risk-info
5
Settlement Agreement with BD and Bard
In April of fiscal 2024, the Company reached a settlement agreement with Becton, Dickinson and Company (BD) and C. R. Bard, Inc. (Bard), putting an end to a decade-long
intellectual property litigation. With this resolution, the Company can now fully dedicate its resources to delivering innovative medical technology solutions and improving patient outcomes.
Initiated Transition of Manufacturing Operations to Fully Outsourced Model
In January of fiscal 2024, the Company announced that it is committed to shifting its manufacturing operations from a company-owned facility in upstate New York to a
fully outsourced model over the next two years. This shift is expected to result in an approximate $15 million annualized reduction in expenses by fiscal year 2027.
Optimization of Med Device Business
In fiscal year 2024, the Company optimized its Med Device business through the divestiture and discontinuation of a number of non-core assets.
Sale of Dialysis Product Portfolio and BioSentry Product
In June of fiscal 2024, the Company completed the sale of its Dialysis product portfolio and BioSentry Tract Sealant System Biopsy product to Merit Medical Systems, Inc. for $100 million in
cash.
Sale of PICC and Midline Product Portfolios
In February of fiscal 2024, the Company completed the sale of its PICC and Midline product portfolios to Spectrum Vascular, for up to $45 million in cash.
At the same time, the Company discontinued the sale of its RadioFrequency products, as well as its Syntrax support catheter products to further streamline its product portfolio.
Repaid $50 Million Credit Agreement, Eliminating All Long-Term Debt
In June of fiscal 2024 and, in conjunction with receipt of proceeds from the sale of its Dialysis product portfolio and BioSentry product, the Company repaid all amounts outstanding under its
then existing $50.0 million Credit Agreement, fully eliminating all long-term debt from its balance sheet.
Conference Call
The Company's management will host a conference call today at 8:00 a.m. ET to discuss its fourth quarter and fiscal year 2024 results.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1- 201-689-8560 (international) and refer to the passcode 13747424.
6
This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the
call.
A recording of the call will also be available from 12:00 p.m. ET on Tuesday, July 16, 2024, until 11:59 p.m. ET on Tuesday, July 23, 2024. To hear this recording, dial
1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13747424.
Use of Non-GAAP Measures
Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in
AngioDynamics' business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics
has reported pro forma results, adjusted EBITDA, adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures
provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics'
underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only
occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer
treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets
to treat unmet patient needs. For more information, visit www.angiodynamics.com.
7
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics'
expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future
operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," “projects”, "optimistic," or variations of such words and similar expressions, are
forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics'
expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing
and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to
effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future
clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party
distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives,
the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability
of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual
Report on Form 10-K for the year ended May 31, 2023. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue and is
similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.
8
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share data)
|
Three Months Ended
|
Three Months Ended
|
|||||||||||||||||||||||
|
Actual (1)
|
Pro Forma Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
May 31, 2024
|
May 31, 2024
|
May 31, 2024
|
May 31, 2023
|
May 31, 2023
|
May 31, 2023
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Net sales
|
$
|
70,980
|
142
|
$
|
71,122
|
$
|
91,074
|
(21,305
|
)
|
$
|
69,769
|
|||||||||||||
|
Cost of sales (exclusive of intangible amortization)
|
32,465
|
56
|
32,521
|
44,715
|
(12,836
|
)
|
31,879
|
|||||||||||||||||
|
Gross profit
|
38,515
|
86
|
38,601
|
46,359
|
(8,469
|
)
|
37,890
|
|||||||||||||||||
|
% of net sales
|
54.3
|
%
|
54.3
|
%
|
50.9
|
%
|
54.3
|
%
|
||||||||||||||||
|
Operating expenses
|
||||||||||||||||||||||||
|
Research and development
|
6,724
|
(1
|
)
|
6,723
|
7,860
|
(224
|
)
|
7,636
|
||||||||||||||||
|
Sales and marketing
|
24,581
|
(17
|
)
|
24,564
|
26,293
|
(1,804
|
)
|
24,489
|
||||||||||||||||
|
General and administrative
|
10,441
|
(7
|
)
|
10,434
|
10,228
|
51
|
10,279
|
|||||||||||||||||
|
Amortization of intangibles
|
2,574
|
—
|
2,574
|
4,406
|
(1,448
|
)
|
2,958
|
|||||||||||||||||
|
Goodwill impairment
|
—
|
—
|
—
|
14,549
|
—
|
14,549
|
||||||||||||||||||
|
Change in fair value of contingent consideration
|
229
|
—
|
229
|
236
|
—
|
236
|
||||||||||||||||||
|
Acquisition, restructuring and other items, net
|
8,415
|
(3
|
)
|
8,412
|
3,624
|
(368
|
)
|
3,256
|
||||||||||||||||
|
Total operating expenses
|
52,964
|
(28
|
)
|
52,936
|
67,196
|
(3,793
|
)
|
63,403
|
||||||||||||||||
|
Operating loss
|
(14,449
|
)
|
114
|
(14,335
|
)
|
(20,837
|
)
|
(4,676
|
)
|
(25,513
|
)
|
|||||||||||||
|
Interest income (expense), net
|
567
|
—
|
567
|
(901
|
)
|
—
|
(901
|
)
|
||||||||||||||||
|
Other expense, net
|
(259
|
)
|
—
|
(259
|
)
|
(127
|
)
|
—
|
(127
|
)
|
||||||||||||||
|
Total other income (expense), net
|
308
|
—
|
308
|
(1,028
|
)
|
—
|
(1,028
|
)
|
||||||||||||||||
|
Loss before income tax expense (benefit)
|
(14,141
|
)
|
114
|
(14,027
|
)
|
(21,865
|
)
|
(4,676
|
)
|
(26,541
|
)
|
|||||||||||||
|
Income tax benefit
|
(692
|
)
|
—
|
(692
|
)
|
(398
|
)
|
—
|
(398
|
)
|
||||||||||||||
|
Net loss
|
$
|
(13,449
|
)
|
$
|
114
|
$
|
(13,335
|
)
|
$
|
(21,467
|
)
|
$
|
(4,676
|
)
|
$
|
(26,143
|
)
|
|||||||
|
Loss per share
|
||||||||||||||||||||||||
|
Basic
|
$
|
(0.33
|
)
|
$
|
(0.33
|
)
|
$
|
(0.54
|
)
|
$
|
(0.66
|
)
|
||||||||||||
|
Diluted
|
$
|
(0.33
|
)
|
$
|
(0.33
|
)
|
$
|
(0.54
|
)
|
$
|
(0.66
|
)
|
||||||||||||
|
Weighted average shares outstanding
|
||||||||||||||||||||||||
|
Basic
|
40,427
|
40,427
|
39,608
|
39,608
|
||||||||||||||||||||
|
Diluted
|
40,427
|
40,427
|
39,608
|
39,608
|
||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the
Dialysis and BioSentry Businesses, the sale of the PICCs and Midlines Businesses and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") for the three months ended May 31, 2024 and May 31, 2023.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the
Businesses.
9
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS
(in thousands, except per share data)
|
Twelve months ended
|
Twelve months ended
|
|||||||||||||||||||||||
|
Actual (1)
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma
Adjustments (2)
|
Pro Forma
|
|||||||||||||||||||
|
May 31, 2024
|
May 31, 2024
|
May 31, 2024
|
May 31, 2023
|
May 31, 2023
|
May 31, 2023
|
|||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||
|
Net sales
|
$
|
303,914
|
(33,193
|
)
|
$
|
270,721
|
$
|
338,752
|
(81,565
|
)
|
$
|
257,187
|
||||||||||||
|
Cost of sales (exclusive of intangible amortization)
|
149,216
|
(24,064
|
)
|
125,152
|
164,506
|
(48,540
|
)
|
115,966
|
||||||||||||||||
|
Gross profit
|
154,698
|
(9,129
|
)
|
145,569
|
174,246
|
(33,025
|
)
|
141,221
|
||||||||||||||||
|
% of net sales
|
50.9
|
%
|
53.8
|
%
|
51.4
|
%
|
54.9
|
%
|
||||||||||||||||
|
Operating expenses
|
||||||||||||||||||||||||
|
Research and development
|
31,512
|
(648
|
)
|
30,864
|
29,883
|
(615
|
)
|
29,268
|
||||||||||||||||
|
Sales and marketing
|
102,818
|
(4,730
|
)
|
98,088
|
104,249
|
(6,109
|
)
|
98,140
|
||||||||||||||||
|
General and administrative
|
41,164
|
(60
|
)
|
41,104
|
40,003
|
(1,190
|
)
|
38,813
|
||||||||||||||||
|
Amortization of intangibles
|
13,048
|
(2,571
|
)
|
10,477
|
18,790
|
(5,790
|
)
|
13,000
|
||||||||||||||||
|
Goodwill impairment
|
159,476
|
—
|
159,476
|
14,549
|
—
|
14,549
|
||||||||||||||||||
|
Change in fair value of contingent consideration
|
432
|
—
|
432
|
2,320
|
—
|
2,320
|
||||||||||||||||||
|
Acquisition, restructuring and other items, net
|
53,182
|
(6,397
|
)
|
46,785
|
15,633
|
(385
|
)
|
15,248
|
||||||||||||||||
|
Total operating expenses
|
401,632
|
(14,406
|
)
|
387,226
|
225,427
|
(14,089
|
)
|
211,338
|
||||||||||||||||
|
Gain on sale of assets
|
54,499
|
(54,499
|
)
|
—
|
—
|
—
|
—
|
|||||||||||||||||
|
Operating loss
|
(192,435
|
)
|
(49,222
|
)
|
(241,657
|
)
|
(51,181
|
)
|
(18,936
|
)
|
(70,117
|
)
|
||||||||||||
|
Interest income (expense), net
|
1,614
|
—
|
1,614
|
(2,702
|
)
|
—
|
(2,702
|
)
|
||||||||||||||||
|
Other expense, net
|
(817
|
)
|
—
|
(817
|
)
|
(554
|
)
|
—
|
(554
|
)
|
||||||||||||||
|
Total other income (expense), net
|
797
|
—
|
797
|
(3,256
|
)
|
—
|
(3,256
|
)
|
||||||||||||||||
|
Loss before income tax expense (benefit)
|
(191,638
|
)
|
(49,222
|
)
|
(240,860
|
)
|
(54,437
|
)
|
(18,936
|
)
|
(73,373
|
)
|
||||||||||||
|
Income tax benefit
|
(7,289
|
)
|
—
|
(7,289
|
)
|
(1,995
|
)
|
—
|
(1,995
|
)
|
||||||||||||||
|
Net loss
|
$
|
(184,349
|
)
|
$
|
(49,222
|
)
|
$
|
(233,571
|
)
|
$
|
(52,442
|
)
|
$
|
(18,936
|
)
|
$
|
(71,378
|
)
|
||||||
|
Loss per share
|
||||||||||||||||||||||||
|
Basic
|
$
|
(4.59
|
)
|
$
|
(5.81
|
)
|
$
|
(1.33
|
)
|
$
|
(1.81
|
)
|
||||||||||||
|
Diluted
|
$
|
(4.59
|
)
|
$
|
(5.81
|
)
|
$
|
(1.33
|
)
|
$
|
(1.81
|
)
|
||||||||||||
|
Weighted average shares outstanding
|
||||||||||||||||||||||||
|
Basic
|
40,181
|
40,181
|
39,480
|
39,480
|
||||||||||||||||||||
|
Diluted
|
40,181
|
40,181
|
39,480
|
39,480
|
||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses, the sale of
the PICCs and Midlines Businesses and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") for the twelve months ended May 31, 2024 and May 31, 2023.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
10
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
(in thousands, except per share data)
Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss):
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2024
|
May 31, 2023
|
May 31, 2024
|
May 31, 2023
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Net loss
|
$
|
(13,449
|
)
|
$
|
(21,467
|
)
|
$
|
(184,349
|
)
|
$
|
(52,442
|
)
|
||||
|
Amortization of intangibles
|
2,574
|
4,406
|
13,048
|
18,790
|
||||||||||||
|
Goodwill impairment
|
—
|
14,549
|
159,476
|
14,549
|
||||||||||||
|
Change in fair value of contingent consideration
|
229
|
236
|
432
|
2,320
|
||||||||||||
|
Acquisition, restructuring and other items, net (1)
|
8,415
|
3,624
|
53,182
|
15,633
|
||||||||||||
|
Gain on sale of assets
|
—
|
—
|
(54,499
|
)
|
—
|
|||||||||||
|
Tax effect of non-GAAP items (2)
|
(20
|
)
|
(617
|
)
|
(2,689
|
)
|
(1,272
|
)
|
||||||||
|
Adjusted net income (loss)
|
$
|
(2,251
|
)
|
$
|
731
|
$
|
(15,399
|
)
|
$
|
(2,422
|
)
|
|||||
Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Earnings (Loss) Per Share:
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2024
|
May 31, 2023
|
May 31, 2024
|
May 31, 2023
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Diluted loss per share
|
$
|
(0.33
|
)
|
$
|
(0.54
|
)
|
$
|
(4.59
|
)
|
$
|
(1.33
|
)
|
||||
|
Amortization of intangibles
|
0.06
|
0.11
|
0.32
|
0.48
|
||||||||||||
|
Goodwill impairment
|
—
|
0.37
|
3.98
|
0.37
|
||||||||||||
|
Change in fair value of contingent consideration
|
0.01
|
0.01
|
0.01
|
0.06
|
||||||||||||
|
Acquisition, restructuring and other items, net (1)
|
0.20
|
0.09
|
1.33
|
0.39
|
||||||||||||
|
Gain on sale of assets
|
—
|
—
|
(1.36
|
)
|
—
|
|||||||||||
|
Tax effect of non-GAAP items (2)
|
—
|
(0.02
|
)
|
(0.07
|
)
|
(0.03
|
)
|
|||||||||
|
Adjusted diluted earnings (loss) per share
|
$
|
(0.06
|
)
|
$
|
0.02
|
$
|
(0.38
|
)
|
$
|
(0.06
|
)
|
|||||
|
|
||||||||||||||||
|
Adjusted diluted sharecount (3)
|
40,427
|
39,916
|
40,181
|
39,480
|
||||||||||||
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other
items.
(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an
effective tax rate of 23% for the periods ended May 31, 2024 and May 31, 2023.
(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.
11
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION (Continued)
(in thousands, except per share data)
Reconciliation of Net Loss to Adjusted EBITDA:
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2024
|
May 31, 2023
|
May 31, 2024
|
May 31, 2023
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Net loss
|
$
|
(13,449
|
)
|
$
|
(21,467
|
)
|
$
|
(184,349
|
)
|
$
|
(52,442
|
)
|
||||
|
Income tax benefit
|
(692
|
)
|
(398
|
)
|
(7,289
|
)
|
(1,995
|
)
|
||||||||
|
Interest expense, net
|
(567
|
)
|
901
|
(1,614
|
)
|
2,702
|
||||||||||
|
Depreciation and amortization
|
6,817
|
7,506
|
27,712
|
30,681
|
||||||||||||
|
Goodwill impairment
|
—
|
14,549
|
159,476
|
14,549
|
||||||||||||
|
Change in fair value of contingent consideration
|
229
|
236
|
432
|
2,320
|
||||||||||||
|
Stock based compensation
|
1,896
|
2,981
|
10,529
|
11,158
|
||||||||||||
|
Gain on sale of assets
|
—
|
—
|
(54,499
|
)
|
—
|
|||||||||||
|
Acquisition, restructuring and other items, net (1)
|
7,148
|
3,624
|
50,780
|
15,633
|
||||||||||||
|
Adjusted EBITDA
|
$
|
1,382
|
$
|
7,932
|
$
|
1,178
|
$
|
22,606
|
||||||||
|
Per diluted share:
|
||||||||||||||||
|
Adjusted EBITDA
|
$
|
0.03
|
$
|
0.20
|
$
|
0.03
|
$
|
0.57
|
||||||||
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other
items.
12
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
(in thousands, except per share data)
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted Net Loss:
|
Pro Forma
|
Pro Forma
|
|||||||||||||||
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2024
|
May 31, 2023
|
May 31, 2024
|
May 31, 2023
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Pro forma net loss
|
$
|
(13,335
|
)
|
$
|
(26,143
|
)
|
$
|
(233,571
|
)
|
$
|
(71,378
|
)
|
||||
|
Amortization of intangibles
|
2,574
|
2,958
|
10,477
|
13,000
|
||||||||||||
|
Goodwill impairment
|
—
|
14,549
|
159,476
|
14,549
|
||||||||||||
|
Change in fair value of contingent consideration
|
229
|
236
|
432
|
2,320
|
||||||||||||
|
Acquisition, restructuring and other items, net (1)
|
8,412
|
3,256
|
46,785
|
15,248
|
||||||||||||
|
Tax effect of non-GAAP items (2)
|
(45
|
)
|
877
|
(1,840
|
)
|
4,504
|
||||||||||
|
Adjusted pro forma net loss
|
$
|
(2,165
|
)
|
$
|
(4,267
|
)
|
$
|
(18,241
|
)
|
$
|
(21,757
|
)
|
||||
Reconciliation of Pro Forma Diluted Loss Per Share to Pro Forma Adjusted Diluted Loss Per Share:
|
Pro Forma
|
Pro Forma
|
|||||||||||||||
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2024
|
May 31, 2023
|
May 31, 2024
|
May 31, 2023
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Pro forma diluted loss per share
|
$
|
(0.33
|
)
|
$
|
(0.66
|
)
|
$
|
(5.81
|
)
|
$
|
(1.81
|
)
|
||||
|
Amortization of intangibles
|
0.06
|
0.07
|
0.26
|
0.33
|
||||||||||||
|
Goodwill impairment
|
—
|
0.37
|
3.97
|
0.38
|
||||||||||||
|
Change in fair value of contingent consideration
|
0.01
|
0.01
|
0.01
|
0.06
|
||||||||||||
|
Acquisition, restructuring and other items, net (1)
|
0.21
|
0.08
|
1.17
|
0.38
|
||||||||||||
|
Tax effect of non-GAAP items (2)
|
—
|
0.02
|
(0.05
|
)
|
0.11
|
|||||||||||
|
Adjusted pro forma diluted loss per share
|
$
|
(0.05
|
)
|
$
|
(0.11
|
)
|
$
|
(0.45
|
)
|
$
|
(0.55
|
)
|
||||
|
|
||||||||||||||||
|
Adjusted diluted sharecount (3)
|
40,427
|
39,608
|
40,181
|
39,480
|
||||||||||||
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other
items
(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company's U.S. deferred tax assets and an
effective tax rate of 23% for the periods ended May 31, 2024 and May 31, 2023.
(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.
13
ANGIODYNAMICS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION (Continued)
(in thousands, except per share data)
Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted EBITDA:
|
Pro Forma
|
Pro Forma
|
|||||||||||||||
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2024
|
May 31, 2023
|
May 31, 2024
|
May 31, 2023
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||
|
Pro forma net loss
|
$
|
(13,335
|
)
|
$
|
(26,143
|
)
|
$
|
(233,571
|
)
|
$
|
(71,378
|
)
|
||||
|
Income tax benefit
|
(692
|
)
|
(398
|
)
|
(7,289
|
)
|
(1,995
|
)
|
||||||||
|
Interest income (expense), net
|
(567
|
)
|
901
|
(1,614
|
)
|
2,702
|
||||||||||
|
Depreciation and amortization
|
6,817
|
6,008
|
25,051
|
24,688
|
||||||||||||
|
Goodwill impairment
|
—
|
14,549
|
159,476
|
14,549
|
||||||||||||
|
Change in fair value of contingent consideration
|
229
|
236
|
432
|
2,320
|
||||||||||||
|
Stock based compensation
|
1,895
|
2,910
|
9,898
|
10,864
|
||||||||||||
|
Acquisition, restructuring and other items, net (1)
|
7,145
|
3,256
|
44,382
|
15,248
|
||||||||||||
|
Pro forma adjusted EBITDA
|
$
|
1,492
|
$
|
1,319
|
$
|
(3,235
|
)
|
$
|
(3,002
|
)
|
||||||
|
Per diluted share:
|
||||||||||||||||
|
Adjusted EBITDA
|
$
|
0.04
|
$
|
0.03
|
$
|
(0.08
|
)
|
$
|
(0.08
|
)
|
||||||
(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other
items.
14
ANGIODYNAMICS, INC. AND SUBSIDIARIES
ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET DETAIL
(in thousands)
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
(in thousands)
|
May 31, 2024
|
May 31, 2023
|
May 31, 2024
|
May 31, 2023
|
||||||||||||
|
Legal (1)
|
$
|
4,489
|
$
|
3,099
|
$
|
34,942
|
$
|
9,998
|
||||||||
|
Mergers and acquisitions (2)
|
—
|
368
|
399
|
368
|
||||||||||||
|
Transition service agreement (3)
|
(437
|
)
|
—
|
(1,092
|
)
|
—
|
||||||||||
|
Plant Closure (4)
|
3,366
|
—
|
9,481
|
—
|
||||||||||||
|
Manufacturing Relocation (5)
|
—
|
29
|
587
|
1,091
|
||||||||||||
|
Intangible and other asset impairment (6)
|
—
|
—
|
6,260
|
—
|
||||||||||||
|
Israeli Innovation Authority prepayment (7)
|
—
|
—
|
—
|
3,544
|
||||||||||||
|
Other (8)
|
997
|
128
|
2,605
|
632
|
||||||||||||
|
Total
|
$
|
8,415
|
$
|
3,624
|
$
|
53,182
|
$
|
15,633
|
||||||||
(1) Legal expenses related to litigation that is outside the normal course of business. In the third quarter of fiscal year 2024 a $19.3 million
settlement expense was recorded as a result of the Settlement Agreement that was entered into between the Company and BD.
(2) Mergers and acquisitions expenses related to investment banking, legal and due diligence.
(3) Transition services agreement that were entered into with Merit and Spectrum.
(4) Plant closure expense, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.
(5) Expenses to relocate manufacturing lines out of Queensbury, NY.
(6) An impairment of $3.4 million on intangible and fixed assets and an inventory write-off of $2.9 million
was taken in the third quarter of fiscal year 2024 relating to the abandonment of the Syntrax and RF product lines.
(7) In the first quarter of fiscal year 2023, a $3.5 million payment was made to the Israeli Innovation Authority to fully satisfy the obligation
related to grant funds that were provided to Eximo for development of the Auryon laser prior to the acquisition in the second quarter of fiscal year 2020.
(8) Included in the $2.6 million in other for the year ended May 31, 2024 is $0.9 million of deferred financing fees that were written-off in conjunction with
the sale of the Dialysis and BioSentry businesses and concurrent extinguishment of the debt.
15
ANGIODYNAMICS, INC. AND SUBSIDIARIES
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
(in thousands)
|
Three Months Ended
|
Three Months Ended
|
||||||||||||||||||||||||||||||||||||||||||||||
|
Actual (1)
|
Pro Forma
Adj. (2)
|
Pro Forma
|
As
Reported (1)
|
Pro Forma
Adj. (2)
|
Pro Forma
|
Actual
|
Pro Forma
|
||||||||||||||||||||||||||||||||||||||||
|
May 31, 2024
|
May 31, 2024
|
May 31, 2024
|
May 31, 2023
|
May 31, 2023
|
May 31, 2023
|
% Growth
|
Currency Impact
|
Constant Currency Growth
|
% Growth
|
Currency Impact
|
Constant Currency Growth
|
||||||||||||||||||||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
||||||||||||||||||||||||||||||||||||||||||||||
|
Net Sales
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
Med Tech
|
$
|
29,335
|
$
|
—
|
$
|
29,335
|
$
|
26,494
|
$
|
(148
|
)
|
$
|
26,346
|
10.7
|
%
|
11.3
|
%
|
||||||||||||||||||||||||||||||
|
Med Device
|
41,645
|
142
|
41,787
|
64,580
|
(21,157
|
)
|
43,423
|
(35.5
|
)%
|
(3.8
|
)%
|
||||||||||||||||||||||||||||||||||||
|
$
|
70,980
|
$
|
142
|
$
|
71,122
|
$
|
91,074
|
$
|
(21,305
|
)
|
$
|
69,769
|
(22.1
|
)%
|
0.0
|
%
|
(22.1
|
)%
|
1.9
|
%
|
0.0
|
%
|
1.9
|
%
|
|||||||||||||||||||||||
|
Net Sales
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
United States
|
$
|
60,743
|
$
|
61
|
$
|
60,804
|
$
|
74,439
|
$
|
(16,121
|
)
|
$
|
58,318
|
(18.4
|
)%
|
4.3
|
%
|
||||||||||||||||||||||||||||||
|
International
|
10,237
|
81
|
10,318
|
16,635
|
(5,184
|
)
|
11,451
|
(38.5
|
)%
|
0.0
|
%
|
(38.5
|
)%
|
(9.9
|
)%
|
||||||||||||||||||||||||||||||||
|
$
|
70,980
|
$
|
142
|
$
|
71,122
|
$
|
91,074
|
$
|
(21,305
|
)
|
$
|
69,769
|
(22.1
|
)%
|
0.0
|
%
|
(22.1
|
)%
|
1.9
|
%
|
0.0
|
%
|
1.9
|
%
|
|||||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses, the sale of
the PICCs and Midlines Businesses and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") for the three months ended May 31, 2024 and May 31 2023.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
GROSS PROFIT BY PRODUCT CATEGORY
(in thousands)
|
Three Months Ended
|
Three Months Ended
|
|||||||||||||||||||||||||||||||
|
Actual (1)
|
Pro Forma
Adj. (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma
Adj. (2)
|
Pro Forma
|
Actual
|
Pro Forma
|
|||||||||||||||||||||||||
|
May 31, 2024
|
May 31, 2024
|
May 31, 2024
|
May 31, 2023
|
May 31, 2023
|
May 31, 2023
|
% Change
|
% Change
|
|||||||||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||||||||||
|
Med Tech
|
$
|
18,798
|
$
|
6
|
$
|
18,804
|
$
|
17,150
|
$
|
(82
|
)
|
$
|
17,068
|
9.6
|
%
|
10.2
|
%
|
|||||||||||||||
|
Gross profit % of sales
|
64.1
|
%
|
64.1
|
%
|
64.7
|
%
|
64.8
|
%
|
||||||||||||||||||||||||
|
Med Device
|
$
|
19,717
|
$
|
80
|
$
|
19,797
|
$
|
29,209
|
$
|
(8,387
|
)
|
$
|
20,822
|
(32.5
|
)%
|
(4.9
|
)%
|
|||||||||||||||
|
Gross profit % of sales
|
47.3
|
%
|
47.4
|
%
|
45.2
|
%
|
48.0
|
%
|
||||||||||||||||||||||||
|
Total
|
$
|
38,515
|
$
|
86
|
$
|
38,601
|
$
|
46,359
|
$
|
(8,469
|
)
|
$
|
37,890
|
(16.9
|
)%
|
1.9
|
%
|
|||||||||||||||
|
Gross profit % of sales
|
54.3
|
%
|
54.3
|
%
|
50.9
|
%
|
54.3
|
%
|
||||||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses, the sale of
the PICCs and Midlines Businesses and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") for the three months ended May 31, 2024 and May 31, 2023.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
16
ANGIODYNAMICS, INC. AND SUBSIDIARIES
NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY
(in thousands)
|
Twelve Months Ended
|
Twelve Months Ended
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
Actual (1)
|
Pro Forma
Adj. (2)
|
Pro Forma
|
As
Reported (1)
|
Pro Forma
Adj. (2)
|
Pro Forma
|
Actual
|
Pro Forma
|
|||||||||||||||||||||||||||||||||||||||||
|
May 31, 2024
|
May 31, 2024
|
May 31, 2024
|
May 31, 2023
|
May 31, 2023
|
May 31, 2023
|
% Growth
|
Currency Impact
|
Constant Currency Growth
|
%
Growth
|
Currency Impact
|
Constant Currency Growth
|
|||||||||||||||||||||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||||||||||||||||||||||||||
|
Net Sales
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Med Tech
|
$
|
106,403
|
$
|
(443
|
)
|
$
|
105,960
|
$
|
96,687
|
$
|
(450
|
)
|
$
|
96,237
|
10.0
|
%
|
10.1
|
%
|
||||||||||||||||||||||||||||||
|
Med Device
|
197,511
|
(32,750
|
)
|
164,761
|
242,065
|
(81,115
|
)
|
160,950
|
(18.4
|
)%
|
2.4
|
%
|
||||||||||||||||||||||||||||||||||||
|
$
|
303,914
|
$
|
(33,193
|
)
|
$
|
270,721
|
$
|
338,752
|
$
|
(81,565
|
)
|
$
|
257,187
|
(10.3
|
)%
|
0.0
|
%
|
(10.3
|
)%
|
5.3
|
%
|
0.0
|
%
|
5.3
|
%
|
|||||||||||||||||||||||
|
Net Sales
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
United States
|
$
|
251,486
|
$
|
(23,037
|
)
|
$
|
228,449
|
$
|
282,713
|
$
|
(62,617
|
)
|
$
|
220,096
|
(11.0
|
)%
|
3.8
|
%
|
||||||||||||||||||||||||||||||
|
International
|
52,428
|
(10,156
|
)
|
42,272
|
56,039
|
(18,948
|
)
|
37,091
|
(6.4
|
)%
|
0.0
|
%
|
(6.4
|
)%
|
14.0
|
%
|
||||||||||||||||||||||||||||||||
|
$
|
303,914
|
$
|
(33,193
|
)
|
$
|
270,721
|
$
|
338,752
|
$
|
(81,565
|
)
|
$
|
257,187
|
(10.3
|
)%
|
0.0
|
%
|
(10.3
|
)%
|
5.3
|
%
|
0.0
|
%
|
5.3
|
%
|
|||||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses, the sale of
the PICCs and Midlines Businesses and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") for the twelve months ended May 31, 2024 and May 31 2023.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
GROSS PROFIT BY PRODUCT CATEGORY
(in thousands)
|
Twelve Months Ended
|
Twelve Months Ended
|
|||||||||||||||||||||||||||||||
|
Actual (1)
|
Pro Forma
Adj. (2)
|
Pro Forma
|
As Reported (1)
|
Pro Forma
Adj. (2)
|
Pro Forma
|
Actual
|
Pro Forma
|
|||||||||||||||||||||||||
|
May 31, 2024
|
May 31, 2024
|
May 31, 2024
|
May 31, 2023
|
May 31, 2023
|
May 31, 2023
|
% Change
|
% Change
|
|||||||||||||||||||||||||
|
(unaudited)
|
(unaudited)
|
|||||||||||||||||||||||||||||||
|
Med Tech
|
$
|
67,198
|
$
|
(167
|
)
|
$
|
67,031
|
$
|
61,966
|
$
|
(234
|
)
|
$
|
61,732
|
8.4
|
%
|
8.6
|
%
|
||||||||||||||
|
Gross profit % of sales
|
63.2
|
%
|
63.3
|
%
|
64.1
|
%
|
64.1
|
%
|
||||||||||||||||||||||||
|
Med Device
|
$
|
87,500
|
$
|
(8,962
|
)
|
$
|
78,538
|
$
|
112,280
|
$
|
(32,791
|
)
|
$
|
79,489
|
(22.1
|
)%
|
(1.2
|
)%
|
||||||||||||||
|
Gross profit % of sales
|
44.3
|
%
|
47.7
|
%
|
46.4
|
%
|
49.4
|
%
|
||||||||||||||||||||||||
|
Total
|
$
|
154,698
|
$
|
(9,129
|
)
|
$
|
145,569
|
$
|
174,246
|
$
|
(33,025
|
)
|
$
|
141,221
|
(11.2
|
)%
|
3.1
|
%
|
||||||||||||||
|
Gross profit % of sales
|
50.9
|
%
|
53.8
|
%
|
51.4
|
%
|
54.9
|
%
|
||||||||||||||||||||||||
(1) Reflects the Company's US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses, the sale of
the PICCs and Midlines Businesses and the discontinuation of the RadioFrequency Ablation and Syntrax products ("the Businesses") for the twelve months ended May 31, 2024 and May 31, 2023.
(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.
17
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands)
|
May 31, 2024
|
May 31, 2023
|
|||||||
|
(unaudited)
|
(audited)
|
|||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
76,056
|
$
|
44,620
|
||||
|
Accounts receivable, net
|
43,610
|
52,826
|
||||||
|
Inventories
|
60,616
|
55,325
|
||||||
|
Prepaid expenses and other
|
12,971
|
4,617
|
||||||
|
Current assets held for sale
|
—
|
6,154
|
||||||
|
Total current assets
|
193,253
|
163,542
|
||||||
|
Property, plant and equipment, net
|
35,666
|
44,384
|
||||||
|
Other assets
|
11,369
|
10,676
|
||||||
|
Intangible assets, net
|
77,383
|
111,144
|
||||||
|
Goodwill
|
—
|
159,238
|
||||||
|
Non-current assets held for sale
|
—
|
43,653
|
||||||
|
Total assets
|
$
|
317,671
|
$
|
532,637
|
||||
|
Liabilities and stockholders' equity
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
37,751
|
$
|
40,445
|
||||
|
Accrued liabilities
|
41,098
|
26,617
|
||||||
|
Current portion of contingent consideration
|
4,728
|
14,761
|
||||||
|
Other current liabilities
|
7,578
|
2,002
|
||||||
|
Total current liabilities
|
91,155
|
83,825
|
||||||
|
Long-term debt, net of current portion
|
—
|
49,818
|
||||||
|
Deferred income taxes
|
4,852
|
12,813
|
||||||
|
Contingent consideration, net of current portion
|
—
|
4,535
|
||||||
|
Other long-term liabilities
|
16,078
|
3,350
|
||||||
|
Total liabilities
|
112,085
|
154,341
|
||||||
|
Stockholders' equity
|
205,586
|
378,296
|
||||||
|
Total Liabilities and Stockholders' Equity
|
$
|
317,671
|
$
|
532,637
|
||||
18
ANGIODYNAMICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
|
Three Months Ended
|
Twelve Months Ended
|
|||||||||||||||
|
May 31, 2024
|
May 31, 2023
|
May 31, 2024
|
May 31, 2023
|
|||||||||||||
|
(unaudited)
|
(unaudited)
|
(audited)
|
||||||||||||||
|
Cash flows from operating activities:
|
||||||||||||||||
|
Net loss
|
$
|
(13,449
|
)
|
$
|
(21,467
|
)
|
$
|
(184,349
|
)
|
$
|
(52,442
|
)
|
||||
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
|
||||||||||||||||
|
Depreciation and amortization
|
6,817
|
7,557
|
27,712
|
30,873
|
||||||||||||
|
Non-cash lease expense
|
490
|
601
|
1,931
|
2,484
|
||||||||||||
|
Goodwill impairment
|
—
|
14,549
|
159,476
|
14,549
|
||||||||||||
|
Stock based compensation
|
1,896
|
2,981
|
10,529
|
11,158
|
||||||||||||
|
Gain on disposition
|
—
|
—
|
(54,499
|
)
|
—
|
|||||||||||
|
Transaction costs for disposition
|
—
|
—
|
(5,084
|
)
|
—
|
|||||||||||
|
Change in fair value of contingent consideration
|
229
|
236
|
432
|
2,320
|
||||||||||||
|
Deferred income tax provision
|
(825
|
)
|
(558
|
)
|
(7,968
|
)
|
(2,311
|
)
|
||||||||
|
Change in accounts receivable allowances
|
319
|
135
|
1,326
|
695
|
||||||||||||
|
Asset impairments and disposals
|
24
|
147
|
7,108
|
291
|
||||||||||||
|
Write-off of other assets
|
—
|
—
|
869
|
—
|
||||||||||||
|
Other
|
(223
|
)
|
(197
|
)
|
(62
|
)
|
(513
|
)
|
||||||||
|
Changes in operating assets and liabilities, net of acquisitions:
|
||||||||||||||||
|
Accounts receivable
|
5,549
|
(2,058
|
)
|
7,894
|
(1,299
|
)
|
||||||||||
|
Inventories
|
(2,585
|
)
|
4,056
|
(9,410
|
)
|
(8,198
|
)
|
|||||||||
|
Prepaid expenses and other
|
(4,028
|
)
|
724
|
(11,594
|
)
|
332
|
||||||||||
|
Accounts payable, accrued and other liabilities
|
10,787
|
9,248
|
27,531
|
2,139
|
||||||||||||
|
Net cash provided by (used in) operating activities
|
5,001
|
15,954
|
(28,158
|
)
|
78
|
|||||||||||
|
Cash flows from investing activities:
|
||||||||||||||||
|
Additions to property, plant and equipment
|
(566
|
)
|
(1,056
|
)
|
(2,518
|
)
|
(3,812
|
)
|
||||||||
|
Additions to placement and evaluation units
|
(1,770
|
)
|
(472
|
)
|
(5,015
|
)
|
(5,394
|
)
|
||||||||
|
Proceeds from sale of assets
|
—
|
—
|
134,500
|
—
|
||||||||||||
|
Acquisition of intangibles
|
—
|
—
|
(3,250
|
)
|
(540
|
)
|
||||||||||
|
Net cash (used in) provided by investing activities
|
(2,336
|
)
|
(1,528
|
)
|
123,717
|
(9,746
|
)
|
|||||||||
|
Cash flows from financing activities:
|
||||||||||||||||
|
Proceeds from issuance of long-term debt
|
—
|
—
|
—
|
70,000
|
||||||||||||
|
Repayment of long-term debt
|
—
|
—
|
(50,000
|
)
|
(45,000
|
)
|
||||||||||
|
Deferred financing costs on long-term debt
|
—
|
—
|
—
|
(751
|
)
|
|||||||||||
|
Payment of acquisition related contingent consideration
|
(5,000
|
)
|
—
|
(15,000
|
)
|
—
|
||||||||||
|
Proceeds from exercise of stock options and employee stock purchase plan
|
—
|
—
|
752
|
1,171
|
||||||||||||
|
Net cash (used in) provided by financing activities
|
(5,000
|
)
|
—
|
(64,248
|
)
|
25,420
|
||||||||||
|
Effect of exchange rate changes on cash and cash equivalents
|
(60
|
)
|
83
|
125
|
43
|
|||||||||||
|
Increase (decrease) in cash and cash equivalents
|
(2,395
|
)
|
14,509
|
31,436
|
15,795
|
|||||||||||
|
Cash and cash equivalents at beginning of period
|
78,451
|
30,111
|
44,620
|
28,825
|
||||||||||||
|
Cash and cash equivalents at end of period
|
$
|
76,056
|
$
|
44,620
|
$
|
76,056
|
$
|
44,620
|
||||||||
19
| 1. |
Learn About Pulmonary Embolism. Lung.org. http://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/learn-about-pulmonary-embolism.
Published 2023.
|
| 2. |
Giri J, Sista AK, Weinberg I, et al. Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for The Development Of Novel Evidence: A Scientific Statement From The American
Heart Association. Circulation 2019;140(20)e774-e801.
|
| 3. |
Willich SN, Chuang LH, van Hout B, Gumbs P, Jimenez D, Kroep S, Bauersachs
R, Monreal M, Agnelli G, Cohen A. Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res. 2018
Oct;170:181-191.
|
| 4. |
Germini F., Zarabi S., Eventov M., Turcotte M., Li M., de Wit K. Pulmonary embolism prevalence among emergency department cohorts: A systematic review
and meta‐analysis by country of study. Journal of Thrombosis and Haemostasis. 2022 Dec; 19(1):173-185
|
20
